Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | HRH1 | P35367 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263181 | 0.90 | KDM4E (0.40) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL19021317 | 0.89 | CYP2D6 (0.43) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL19021335 | 0.89 | KCNH2 (0.50) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL30531188 | 0.89 | USP2 (0.50) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL22345044 | 0.89 | USP2 (0.50) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL19021763 | 0.88 | KCNH2 (0.49) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL19021905 | 0.86 | CYP2D6 (0.41) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL19021867 | 0.85 | USP2 (0.67) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL30531145 | 0.85 | USP2 (0.67) | USP2POLBKCNH2HRH1CYP2D6 | |
| SCHEMBL26263188 | 0.82 | P2RX3 (0.41) | USP2POLBKCNH2HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752128-B2 | Benzimidazoles and indoles as taro inhibitors | MERCK SHARP & DOHME CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3389785-B1 | BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20210346344-A1 | BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11141403-B2 | Benzimidazoles and indoles as taro inhibitors | MERCK SHARP & DOHME CORP (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200261410-A1 | BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141403-B2 | Benzimidazoles and indoles as taro inhibitors | CSDE1, IDO1, TMBIM6 | USP2 4637/4885POLB 343/4885KCNH2 2454/4885 |
| US-20210346344-A1 | BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS | CSDE1, IDO1, TMBIM6 | USP2 4637/4885POLB 343/4885KCNH2 2454/4885 |
| US-11752128-B2 | Benzimidazoles and indoles as taro inhibitors | CSDE1, IDO1, TMBIM6 | USP2 4637/4885POLB 343/4885KCNH2 2454/4885 |
| US-20200261410-A1 | BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS | CSDE1, IDO1, TMBIM6 | USP2 4637/4885POLB 343/4885KCNH2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.